Industry
Neurogene Inc.
Total Trials
6
Recruiting
1
Active
2
Completed
2
Success Rate
50.0%-37% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 90/100
Failure Rate
33.3%
2 terminated/withdrawn out of 6 trials
Success Rate
50.0%
-36.5% vs industry average
Late-Stage Pipeline
17%
1 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed trials have results
Key Signals
1 recruiting
Enrollment Performance
Analytics
Phase 1
2(66.7%)
Phase 3
1(33.3%)
3Total
Phase 1(2)
Phase 3(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (6)
Showing 6 of 6 trials
NCT05898620Phase 3Recruiting
A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome
Role: lead
NCT04659629Phase 1Completed
NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer
Role: lead
NCT05228145Phase 1Active Not Recruiting
Gene Therapy Study for Children With CLN5 Batten Disease
Role: lead
NCT03822650Completed
A Natural History Study of Neuronal Ceroid Lipofuscinosis Type 5 (CLN5)
Role: lead
NCT03853876Terminated
A Natural History Study of Aspartylglucosaminuria
Role: lead
NCT03810508Terminated
A Natural History Study of Charcot-Marie-Tooth 4J (CMT4J)
Role: lead
All 6 trials loaded